MII PR MTB Studie - MII IG Kerndatensatz-Modul Molekulares Tumorboard v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Resource Profile: MII PR MTB Studie - Examples

Active as of 2026-09-15

Examples for the mii-pr-mtb-studie Profile.

CCNE1

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

TEDOVA

IG © 2024+ Medizininformatik-Initiative. Package de.medizininformatikinitiative.kerndatensatz.mtb#2027.0.0-ballot.1 based on FHIR 4.0.1. Generated 2026-09-15
Links: Table of Contents | QA Report | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Legal notice
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.